Triazine formulations with a second active ingredient and surfactant(s)
US-2022265665-A1 · Aug 25, 2022 · US
US12097205B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12097205-B2 |
| Application number | US-201917293100-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 23, 2019 |
| Priority date | Nov 29, 2018 |
| Publication date | Sep 24, 2024 |
| Grant date | Sep 24, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An aqueous composition includes a dihydrotriazine compound of the general formula below, where R 1 means (i) a phenyl group or phenylalkyl group, (ii) a naphthyl group or naphthylalkyl group, (iii) a heterocyclic group, heterocyclic alkyl group or heterocyclic aminoalkyl group, (iv) an alkyl group having 1 to 16 carbon atoms or (v) a cycloalkyl group or cycloalkylalkyl group, R 1 ′ means a hydrogen atom bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R 2 and R 3 each mean a hydrogen atom or a methyl group, R 4 means an alkyl group having 7 to 16 carbon atoms and the dashed line indicates that a double bond is positioned either between positions 1 and 2 or between positions 2 and 3 of the dihydrotriazine ring, or a tautomer thereof or a salt thereof and a defoamer.
Opening claim text (preview).
The invention claimed is: 1. An aqueous composition comprising: a dihydrotriazine compound of the general formula I below: wherein R 1 is (i) a phenyl group or a phenylalkyl group which is substituted with 1 to 3 substituents selected from the group consisting of C 1-6 -alkoxy group, hydroxy group, a halogen atom, C 1-6 -haloalkyl group, C 1-6 -alkyl group, a sulfonamido group and C 1-6 -haloalkoxy group, (ii) a naphthyl group or a naphthylalkyl group, (iii) a heterocyclic group, a heterocyclic alkyl group or a heterocyclic aminoalkyl group, (iv) an alkyl group having 1 to 16 carbon atoms or (v) a cycloalkyl group or a cycloalkylalkyl group, R′ is a hydrogen atom which is bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R 2 and R 3 independently of one another mean is a hydrogen atom or a methyl group, R 4 is an alkyl group having 7 to 16 carbon atoms and the dashed line indicates that the position of a double bond is either between positions 1 and 2 or between positions 2 and 3 of the dihydrotriazine ring, or a tautomer thereof or a salt thereof and a defoamer. 2. The aqueous composition as claimed in claim 1 , wherein R 1 is a phenyl group or a phenylalkyl group which is substituted by 1 to 3 substituents selected from the group consisting of fluorine atom, chlorine atom, hydroxy group, methyl group, tert-butyl group, trifluoromethyl group and methoxy group, R 1 ′ is a hydrogen atom which is bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R 2 and R 3 both mean a methyl group and R 4 is an n-octyl group, n-nonyl group or n-decyl group. 3. The aqueous composition as claimed in claim 2 , wherein the phenylalkyl group is benzyl group. 4. The aqueous composition as claimed in claim 1 , wherein R 1 is a phenyl group, 4-chlorophenyl group, 2,4-difluorophenyl group, 2,3,4-trifluorophenyl group, 4-tert-butylphenyl group, 4-methoxyphenyl group, 2-methoxy-4-tert-butylphenyl group, 4-trifluoromethoxyphenyl group, benzyl group, methylbenzyl group, 4-methylbenzyl group, 4-methoxybenzyl group, 3,4-dimethoxybenzyl group, 4-hydroxybenzyl group, 3,4-dichlorobenzyl group, 2,3,4-trichlorobenzyl group, 4-trifluoromethylbenzyl group, 1-phenylethyl group, 2-phenylethyl group, 1-phenylpropyl group, 2-phenylpropyl group or 3-phenylpropyl group, R 1 ′ means is a hydrogen atom which is bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R 2 and R 3 both mean a methyl group and R 4 is an n-octyl group, n-nonyl group or n-decyl group. 5. The aqueous composition as claimed in claim 1 , wherein R 1 is a methylbenzyl group, and/or R 2 and R 3 both mean a methyl group and/or R 4 is an n-octyl group. 6. The aqueous composition as claimed in claim 5 , wherein the methylbenzyl group is 4-methylbenzyl group. 7. The aqueous composition as claimed in claim 1 , wherein R 1 means is a methylbenzyl group, R 1 ′ is a hydrogen atom which is bonded to the nitrogen atom at position 1 or 3 of the dihydrotriazine ring, R 2 and R 3 both mean a methyl group and R 4 is an n-octyl group. 8. The aqueous composition as claimed in claim 7 , wherein the methylbenzyl group is 4-methylbenzyl group. 9. The aqueous composition as claimed in claim 1 , wherein the dihydrotriazine compound is 4-octylamino-1,6-dihydro-6,6-dimethyl-2-(4′-methylbenzylamino)-1,3,5-triazine gluconate, 4-octylamino-3,6-dihydro-6,6-dimethyl-2-(4′-methylbenzylamino)-1,3,5-triazine gluconate, or a tautomer thereof. 10. The aqueous composition as claimed in claim 1 , wherein the dihydrotriazine compound has a proportion of 0.001% by weight to 1.00% by weight based on the total weight of the aqueous composition. 11. The aqueous composition as claimed in claim 1 , wherein the defoamer is selected from the group consisting of alkyl amide, silicone, poloxamer and combinations of at least two of the defoamers mentioned. 12. The aqueous composition as claimed in claim 1 , wherein the defoamer has a proportion of 0.0001% by weight to 2.0% by weight based on the total weight of the aqueous composition. 13. The aqueous composition as claimed in claim 1 , wherein the aqueous composition further comprises a surfactant, the defoamer and the surfactant being different from one another. 14. The aqueous composition as claimed in claim 13 , wherein the surfactant has an active proportion of 0.01% by weight to 10.0% by weight based on the total weight of the aqueous composition, and/or the emulsifier has a proportion of 0.001% by weight to 1.5% by weight based on the total weight of the aqueous composition. 15. The aqueous composition as claimed in claim 13 , wherein the surfactant is a nonionic surfactant. 16. The aqueous composition as claimed in claim 13 , wherein the surfactant is selected from the group consisting of poloxamer, fatty alcohol alkoxylate, polyvinylpyrrolidone, alkyl polyglucoside and combinations of at least two of the surfactants mentioned. 17. The aqueous composition as claimed in claim 1 , wherein the surfactant is a zwitterionic surfactant. 18. The aqueous composition as claimed in claim 17 , wherein the zwitterionic surfactant is an alkylamidoalkyl betaine. 19. The aqueous composition as claimed in claim 18 , wherein the alkylamidoalkyl betaine is an alkylamidoethyl betaine, alkylamidopropyl betaine or a combination thereof. 20. The aqueous composition as claimed in claim 1 , wherein the aqueous composition further comprises an emulsifier and a surfactant, the emulsifier and the surfactant being different from one another. 21. The aqueous composition as claimed in claim 20 , wherein the emulsifier is selected from the group consisting of alcohol ethoxylate, alkyl polyglucoside, polysorbate, ethoxylated castor oil and combinations of at least two of the emulsifiers mentioned. 22. The aqueous composition as claimed in claim 1 , wherein the aqueous composition further comprises an additive selected from the group consisting of thickener, complexing agent, humectant, acid, alkali, organic solvent and combinations of at least two of the additives mentioned. 23. The aqueous composition as claimed in claim 1 , wherein the aqueous composition is in the form of an aqueous solution or a hydrogel. 24. A method for preventing or treating mucosa and/or wounds and/or infections and/or infectious diseases comprising the step of administering an aqueous composition as claimed in claim 1 to a patient.
Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title
Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} · CPC title
Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title
Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide · CPC title
Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.